CRISPR gene editing shows potential for treating genetic diseases. Explore how it may impact Down syndrome treatment and ...

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

Discover key insights from Vertex, Inc.'s Q2 2025 earnings: solid revenue growth, macro challenges, and a focus on e-invoicing opportunities.

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago. These figures are ...

The Legend of Zelda has become quite the epic tale, spanning decades and many games. You might not think the games are connected, but there is a timeline.